- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
- Interventions
- Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Ipilimumab, Multigated Acquisition Scan, Nivolumab, Quality-of-Life Assessment, Trametinib Dimethyl Sulfoxide
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 839
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 529 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 957
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
- Interventions
- Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 365
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more
- Conditions
- Melanoma (Skin)
- Interventions
- interleukin-2, filgrastim, interferon alfa, cisplatin, dacarbazine, vinblastine
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2012
- U.S. locations
- 296
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 197 more
- Conditions
- Depression
- Interventions
- VNS Therapy
- Device
- Lead sponsor
- Cyberonics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Sacramento, California • Marietta, Georgia + 21 more
- Conditions
- Breast Cancer
- Interventions
- conventional surgery, Sentinel node resection followed by node examination
- Procedure
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5,611 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2014
- U.S. locations
- 68
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Duarte, California + 61 more
- Conditions
- Bipolar Disorder, Transcranial Magnetic Stimulation
- Interventions
- Transcranial Magnetic Stimulation (TMS)
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Interventions
- Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Docetaxel, Gemcitabine, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Questionnaire Administration, Sacituzumab Govitecan
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 159
- States / cities
- Phoenix, Arizona • Irvine, California • Orange, California + 125 more
- Conditions
- Substance Use
- Interventions
- ATTC strategy, ISF strategy
- Behavioral
- Lead sponsor
- RTI International
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Claremont, California • Irvine, California + 32 more
- Conditions
- Atrial Fibrillation, Stroke, Embolism
- Interventions
- Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo)
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14,269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 295
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more
- Conditions
- Atherosclerotic Cardiovascular Disease, Overweight, Obesity
- Interventions
- Maridebart Cafraglutide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 45 Years to 99 Years
- Enrollment
- 12,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 139
- States / cities
- Daphne, Alabama • Fairhope, Alabama • Huntsville, Alabama + 116 more
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Biospecimen Collection, Carboplatin, Cediranib Maleate, Computed Tomography, Echocardiography Test, Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study, Quality-of-Life Assessment
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 579 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 337
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 256 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- NNC0480-0389, Semaglutide, Placebo (NNC080-0389), Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 71
- States / cities
- Anniston, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more
- Conditions
- Schizophrenia
- Interventions
- bifeprunox, risperidone
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 66
- States / cities
- Little Rock, Arkansas • Anaheim, California • Boynton Beach, California + 52 more
- Conditions
- Cerebral Palsy
- Interventions
- Transcranial Direct Current Stimulation (tDCS)
- Device
- Lead sponsor
- Spaulding Rehabilitation Hospital
- Other
- Eligibility
- 8 Years to 18 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Primary Mediastinal Large B-Cell Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, Filgrastim, Lumbar Puncture, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Prednisolone, Prednisone, Radiation Therapy, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 215
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more
- Conditions
- Sarcoma
- Interventions
- cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, zoledronic acid, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, filgrastim, Mesna
- Drug · Procedure · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 40 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 70 more
- Conditions
- Major Depressive Disorder
- Interventions
- Quetiapine fumarate, Duloxetine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 31 more
- Conditions
- Bipolar Disorder
- Interventions
- Transcranial Magnetic Stimulation (TMS), Sham (placebo) TMS
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 24 Years to 65 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Charlestown, Massachusetts • Philadelphia, Pennsylvania
- Conditions
- Psychosis
- Interventions
- Active TMS, Placebo TMS
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Ovarian Cancer
- Interventions
- oregovomab
- Drug
- Lead sponsor
- Unither Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 62
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 54 more
- Conditions
- Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart Failure
- Interventions
- Ranolazine
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 1,012 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 83
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • East Palo Alto, California + 70 more
- Conditions
- Bipolar I
- Interventions
- Aripiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 748 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 62 more
- Conditions
- Medulloblastoma
- Interventions
- Cisplatin, Craniospinal Irradiation, Cyclophosphamide, Involved-Field Radiation Therapy, Laboratory Biomarker Analysis, Lomustine, Quality-of-Life Assessment, Radiation Therapy, Vincristine Sulfate
- Drug · Radiation · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2024
- U.S. locations
- 174
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 132 more
- Conditions
- Alzheimer Disease
- Interventions
- bapineuzumab, placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 88 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 111
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 54 more